Skip to main content
Erschienen in: World Journal of Surgery 10/2018

24.04.2018 | Original Scientific Report with Video

Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience

verfasst von: A. Arjona-Sanchez, S. Rufian-Peña, J. M. Sanchez-Hidalgo, A. Casado-Adam, A. Cosano-Alvarez, J. Briceño-Delgado

Erschienen in: World Journal of Surgery | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard treatment in patients with carcinomatosis peritoneal from different origins. The use of a minimally invasive approach for this high complex procedure might be an alternative that provides them less morbidity and faster recovery with similar oncologic outcomes.

Methods

We describe the initial experience of CRS and HIPEC done via the laparoscopic route in patients with minimal peritoneal metastases in our Unit from March 2016 to January 2018.

Results

A total of eight patients were operated by this minimally invasive approach. The different diagnoses were low-grade pseudomyxoma peritonei (2), benign multicystic mesothelioma (2), primary epithelial ovarian carcinomatosis (2) and locally advanced colon carcinoma T4 (2). The median age was 54 (20–62) years, the median PCI was 3 (2–4), the median operative time was 287 min (240–360), complete cytoreduction CC0 was achieved in all the patients, and no major morbidity was observed. The median length of stay was 4.75 days (4–5). After a median follow-up of 9.5 months, no relapse has been observed.

Conclusion

The results suggest that this minimally invasive approach for CRS and HIPEC is feasible and safe in a highly selected group of patients with peritoneal surface malignancies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Newton AD, Bartlett EK, Karakousis GC (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol 7(1):99–111PubMedPubMedCentral Newton AD, Bartlett EK, Karakousis GC (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol 7(1):99–111PubMedPubMedCentral
2.
Zurück zum Zitat Sommariva A, Zagonel V, Rossi CR (2012) The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 19:3737–3744CrossRefPubMed Sommariva A, Zagonel V, Rossi CR (2012) The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 19:3737–3744CrossRefPubMed
3.
Zurück zum Zitat Patriti A, Cavazzoni E, Graziosi L et al (2008) Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech 18(4):426–428CrossRefPubMed Patriti A, Cavazzoni E, Graziosi L et al (2008) Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech 18(4):426–428CrossRefPubMed
4.
Zurück zum Zitat Facchiano E, Scaringi S, Kianmanesh R et al (2007) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34:154–158CrossRefPubMed Facchiano E, Scaringi S, Kianmanesh R et al (2007) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34:154–158CrossRefPubMed
5.
Zurück zum Zitat Muñoz-Casares FC, Rufián S, Arjona-Sánchez Á et al (2011) Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. Cancer Chemother Pharmacol 68:267CrossRefPubMed Muñoz-Casares FC, Rufián S, Arjona-Sánchez Á et al (2011) Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. Cancer Chemother Pharmacol 68:267CrossRefPubMed
6.
Zurück zum Zitat Park SY, Choi GS, Park JS, Kim HJ et al (2014) Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center. Surg Endosc 28(5):1555–1562CrossRefPubMed Park SY, Choi GS, Park JS, Kim HJ et al (2014) Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center. Surg Endosc 28(5):1555–1562CrossRefPubMed
7.
Zurück zum Zitat Esquivel J, Averbach A, Chua TC (2011) Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 253:764–768CrossRefPubMed Esquivel J, Averbach A, Chua TC (2011) Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg 253:764–768CrossRefPubMed
8.
Zurück zum Zitat Esquivel J, Averbach A (2012) Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin. Gastroenterol Res Pract 2012:981245CrossRefPubMedPubMedCentral Esquivel J, Averbach A (2012) Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin. Gastroenterol Res Pract 2012:981245CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Passot G, Bakrin N, Isaac S, Decullier E, Gilly FN, Glehen O, Cotte E (2013) Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Eur J Surg Oncol 40:957–962CrossRefPubMed Passot G, Bakrin N, Isaac S, Decullier E, Gilly FN, Glehen O, Cotte E (2013) Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Eur J Surg Oncol 40:957–962CrossRefPubMed
10.
Zurück zum Zitat Jayakrishnan TT, Zacharias AJ, Sharma A et al (2014) Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World J Surg Oncol 21(12):270CrossRef Jayakrishnan TT, Zacharias AJ, Sharma A et al (2014) Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). World J Surg Oncol 21(12):270CrossRef
11.
Zurück zum Zitat Ferron G, Gesson-Paute A, Classe JM, Querleu D (2005) Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study. Gynecol Oncol 99:358–361CrossRefPubMed Ferron G, Gesson-Paute A, Classe JM, Querleu D (2005) Feasibility of laparoscopic peritonectomy followed by intra-peritoneal chemohyperthermia: an experimental study. Gynecol Oncol 99:358–361CrossRefPubMed
12.
Zurück zum Zitat Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B et al (2012) High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg 256(6):1084–1088CrossRefPubMed Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B et al (2012) High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg 256(6):1084–1088CrossRefPubMed
13.
Zurück zum Zitat Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907CrossRefPubMed Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907CrossRefPubMed
14.
Zurück zum Zitat Gouy S, Belghiti J, Uzan C, Canlorbe G, Gauthier T, Morice P (2013) Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy. Int J Gynecol Cancer 23(9):1699–1703CrossRefPubMed Gouy S, Belghiti J, Uzan C, Canlorbe G, Gauthier T, Morice P (2013) Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy. Int J Gynecol Cancer 23(9):1699–1703CrossRefPubMed
15.
Zurück zum Zitat Garofalo A, Valle M (2009) Laparoscopy in the management of peritoneal carcinomatosis. Cancer J 15(3):190–195CrossRefPubMed Garofalo A, Valle M (2009) Laparoscopy in the management of peritoneal carcinomatosis. Cancer J 15(3):190–195CrossRefPubMed
Metadaten
Titel
Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience
verfasst von
A. Arjona-Sanchez
S. Rufian-Peña
J. M. Sanchez-Hidalgo
A. Casado-Adam
A. Cosano-Alvarez
J. Briceño-Delgado
Publikationsdatum
24.04.2018
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 10/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-018-4634-6

Weitere Artikel der Ausgabe 10/2018

World Journal of Surgery 10/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.